This is a prospective single arme real-world study clinical study, which aims to investigate the overall benefit and safety of consolidative therapy in advanced NSCLC (stage III/IV) patients , who do not progress after front line systemic therapy (chemotherapy, target therapy or immunological checkpoint inhibitors).
Male or female, age >= 18 years, with life expectancy of at least 12 weeks.
Patients with histologically documented metastatic (stage IV) non-small cell lung cancer.
Subjected to driving genes examination including EGFR, ALK and ROS1.
Achieve complete response (CR)/partial response (PR)/stable disease (SD) after front line systemic treatment (chemotherapy, targeted therapy or immunological checkpoint inhibitors).
Stage I-III a NSCLC completing radical treatment , then undergoing systemic anti-cancer treatment after recurrence.
Patients with PFS no more than 3 months. to first line theray.
Patients with history of any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).
Prior palliative surgery or other local therapy specifically directed against advanced lung cancer.
Single group
local consolidative treatment
Other interventionlocal consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy
Progression free survival
month
Response rate
percentage(%)
Lung Cancer Symptom Scale
quality of life
overall survival
month
Click on the lead sponsor to view all of their trials.
